Evidence supporting the use of: High amylose polysaccharide
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

High amylose polysaccharide, particularly in the form of high amylose maize starch (HAMS), has been investigated for its potential to support gut health and modulate inflammatory bowel diseases like Crohn's Disease. The rationale behind its use is largely based on its function as a resistant starch, which escapes digestion in the small intestine and is fermented by colonic bacteria to produce short-chain fatty acids (SCFAs) such as butyrate. Butyrate is known for its anti-inflammatory properties and beneficial effects on the colonic mucosa.

Several preclinical studies, including animal models of colitis, have demonstrated that supplementation with high amylose starch can reduce intestinal inflammation and improve gut barrier function. Some small-scale human studies and pilot trials in patients with Crohn’s Disease or ulcerative colitis have reported increased SCFA production and potential improvements in disease markers. However, results are mixed, and sample sizes are generally small. No large-scale, definitive randomized controlled trials have established high amylose polysaccharide as a clinically validated treatment for Crohn’s Disease.

In summary, the use of high amylose polysaccharide for Crohn’s Disease is supported by plausible mechanisms and preliminary evidence from animal and early human studies, but current scientific support is modest and insufficient for strong clinical recommendations. More research, especially well-powered human clinical trials, is needed to confirm efficacy and safety.

More about High amylose polysaccharide
More about Crohn's Disease

Products containing High amylose polysaccharide

We currently have no products on Vitabase that contain this ingredient.